Aclidinium bromide

Drug Profile

Aclidinium bromide

Alternative Names: Aclinidinium; Bretaris Genuair; Eklira Genuair; KRP-AB1102; LAS-34273; Tudorza Pressair; TudorzaGenuair

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Almirall-Prodesfarma
  • Developer Almirall S.A.; Daewoong Pharmaceutical; Forest Laboratories; Kyorin Pharmaceutical
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Quinuclidines; Small molecules; Tropanes
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • No development reported Asthma

Most Recent Events

  • 20 May 2015 Launched for Chronic obstructive pulmonary disease in Japan (Inhalation)
  • 26 Mar 2015 Registered for Chronic obstructive pulmonary disease in Japan (Inhalation) ,
  • 03 Mar 2015 AstraZeneca acquires rights to aclidinium bromide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top